NCT07333716RecruitingPhase 2
Desloratadine in Patients With Ulcerative Colitis
Efficacy and Safety of Desloratadine as Adjuvant Therapy in Patients With Ulcerative Colitis
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 1 Jan 2026
- Start date
- 26 Jan 2026
- Primary completion date
- Feb 2027
- Lead sponsor
- Tanta University
- Diseases
- Ulcerative colitis
- NCT number
- NCT07333716
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 44
- From 26 Jan 2026 to the primary completion date, Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with systemic or rectal steroids
- Treatment with immunosuppressant or biological therapies
Other illness
- Known allergy to desloratadine or any ingredient in the formulation
- Patients with other inflammatory diseases
- Patients with history of colon cancer
Other
- Patients with severe UC
- Significant liver or kidney function abnormalities
- Pregnant or lactating females
- Patients with complete or partial colectomy
Who the study is looking for
- Both male and female sex.
- patients with age ranged from 18 to 65.
- patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline.
- Patients treated with 5-aminosalisylic acid (mesalamine).
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Menofia university Hospitals Coordinator of this site? Confirm its status | Shibīn al Kawm | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.